Top Buy
| Security | Buy | Sell | Buy (1M) | Sell (1M) | Price | Target price ▲ | Potential |
|---|---|---|---|---|---|---|---|
| Incyte Corp. | 12 | 2 | 2 | 0 | €52.80 | €78.42 | 48.527% |
| Intra-Cellular Therapies Inc. | 25 | 0 | 2 | 0 | €60.00 | €79.55 | 32.591% |
| Cytokinetics Inc. | 31 | 2 | 9 | 1 | €45.80 | €83.06 | 81.348% |
| Ultragenyx Pharmaceutical Inc. | 17 | 1 | 1 | 0 | €35.40 | €84.74 | 139.390% |
| Aveo Pharmaceuticals Inc. | 1 | 0 | 0 | 0 | €13.85 | €100.00 | 622.022% |
| Axsome Therapeutics Inc | 2 | 0 | 0 | 0 | €68.80 | €100.00 | 45.349% |
| Abbott Laboratories | 17 | 0 | 1 | 0 | €93.40 | €116.71 | 24.960% |
| Merck & Co. Inc. | 28 | 1 | 0 | 0 | €114.80 | €124.92 | 8.817% |
| Neurocrine Bioscience | 31 | 0 | 8 | 0 | €126.20 | €140.60 | 11.413% |
| AbbVie Inc. | 22 | 0 | 2 | 0 | €143.80 | €175.11 | 21.774% |
| Krystal Biotech | 18 | 0 | 2 | 0 | €146.35 | €179.60 | 22.716% |
| Repligen Corp. | 13 | 0 | 1 | 0 | €135.40 | €184.76 | 36.455% |
| Zoetis Inc. A | 23 | 1 | 3 | 0 | €156.48 | €200.06 | 27.849% |
| Alnylam Pharmace. | 36 | 0 | 2 | 0 | €138.50 | €236.30 | 70.612% |
| Charles River Labs Intl | 10 | 0 | 1 | 0 | €195.70 | €248.57 | 27.016% |
| United Therapeutics | 19 | 0 | 4 | 0 | €244.80 | €287.40 | 17.402% |
| Biogen Inc. | 50 | 1 | 7 | 0 | €203.60 | €293.22 | 44.020% |
| Amgen Inc. | 25 | 0 | 4 | 0 | €279.15 | €296.16 | 6.092% |
| Vertex Pharmaceuticals Inc. | 47 | 2 | 7 | 0 | €405.60 | €409.07 | 0.855% |
| Medpace Holdings Inc | 11 | 0 | 2 | 0 | €358.80 | €419.64 | 16.956% |
| Eli Lilly Corp. | 50 | 0 | 7 | 0 | €755.40 | €786.51 | 4.118% |
| Regeneron Pharmaceuticals Inc. | 36 | 1 | 3 | 0 | €889.40 | €958.32 | 7.749% |